RetinalGenix Technologies Inc (RTGN) Cổ tức

RetinalGeniX Technologies, Inc. operates as a medical device company. The company is headquartered in Petaluma, California. The company went IPO on 2022-01-07. The firm's proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. Its RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians available 24/7. The company is also engaged in the development of its product candidates: RTG-2023 and RTG-2024. RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD). RTG-2024 for the treatment of Alzheimer’s syndrome dementia.